Congratulations to Co-Founder and Managing Partner Thomas Goss and his coauthors on the recent publication of their payer budget impact study demonstrating the cost savings associated with the use of the PreciseBreast™ (also referred to as PDxBr) test compared to standard of care (SOC) risk assessment in a cohort of U.S. women with early-stage invasive breast cancer to aid in the treatment decision process (i.e. use of chemotherapy). The study compared the costs of treatment guided by the SOC risk assessment (i.e., 21 gene expression test and histopathology assessment) versus PreciseBreast™ in conjunction with SOC in a hypothetical U.S. commercial health plan of one million U.S. women, with an estimated 1,603 women in the plan diagnosed with early-stage invasive breast cancer. The study reports that use of PreciseBreast™ results in cost savings of $4M in year one compared to the current standard of care alone, with savings increasing to $12.5M over 6 years.
See the press release here: https://lnkd.in/eRD4UnVe
Link to the article here: https://lnkd.in/eXZDMxjj
